Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact

Dow Jones06-17 19:33

By Katherine Hamilton

Jazz Pharmaceuticals and AbCellera agreed to a deal worth up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors.

The agreement includes plans for preclinical research collaboration, options and licensing of T-cell engaging multispecific antibodies.

AbCellera, which has a T-cell engager platform, will perform discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months.

Jazz is granted an option in connection with each research program and, once it exercises its option, will have exclusive, global rights to develop and commercialize each program.

AbCellera will receive $56 million in total upfront payments for the first two research programs, plus an additional $28 million due when the third program starts.

If Jazz exercises its option for development, AbCellera will also be eligible to receive up to $792 million per program in option fees and development, regulatory and commercial sales milestone payments.

AbCellera will also be eligible to receive tiered royalties on net sales ranging from the mid-single digits to the low double digits.

Jazz and AbCellera can also agree to start up to two additional programs. AbCellera can conduct certain activities for investigational new drug-enabling studies and can manufacture clinical supplies for any program under the collaboration.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

June 17, 2026 07:33 ET (11:33 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644743145?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644743145","market":"nz","top_or_hot":-1,"title":"Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Jazz Pharmaceuticals and AbCellera agreed to a deal worth up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors. \n</p>\n<p>\n  The agreement includes plans for preclinical research collaboration, options and licensing of T-cell engaging multispecific antibodies. \n</p>\n<p>\n  AbCellera, which has a T-cell engager platform, will perform discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months. \n</p>\n<p>\n  Jazz is granted an option in connection with each research program and, once it exercises its option, will have exclusive, global rights to develop and commercialize each program. \n</p>\n<p>\n  AbCellera will receive $56 million in total upfront payments for the first two research programs, plus an additional $28 million due when the third program starts. \n</p>\n<p>\n  If Jazz exercises its option for development, AbCellera will also be eligible to receive up to $792 million per program in option fees and development, regulatory and commercial sales milestone payments. \n</p>\n<p>\n  AbCellera will also be eligible to receive tiered royalties on net sales ranging from the mid-single digits to the low double digits. \n</p>\n<p>\n  Jazz and AbCellera can also agree to start up to two additional programs. AbCellera can conduct certain activities for investigational new drug-enabling studies and can manufacture clinical supplies for any program under the collaboration. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 17, 2026 07:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-17 19:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Jazz Pharmaceuticals and AbCellera agreed to a deal worth up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors. \n</p>\n<p>\n  The agreement includes plans for preclinical research collaboration, options and licensing of T-cell engaging multispecific antibodies. \n</p>\n<p>\n  AbCellera, which has a T-cell engager platform, will perform discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months. \n</p>\n<p>\n  Jazz is granted an option in connection with each research program and, once it exercises its option, will have exclusive, global rights to develop and commercialize each program. \n</p>\n<p>\n  AbCellera will receive $56 million in total upfront payments for the first two research programs, plus an additional $28 million due when the third program starts. \n</p>\n<p>\n  If Jazz exercises its option for development, AbCellera will also be eligible to receive up to $792 million per program in option fees and development, regulatory and commercial sales milestone payments. \n</p>\n<p>\n  AbCellera will also be eligible to receive tiered royalties on net sales ranging from the mid-single digits to the low double digits. \n</p>\n<p>\n  Jazz and AbCellera can also agree to start up to two additional programs. AbCellera can conduct certain activities for investigational new drug-enabling studies and can manufacture clinical supplies for any program under the collaboration. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 17, 2026 07:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2644743145","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644743145","pubTimestamp":1781695980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Jazz Pharmaceuticals and AbCellera agreed to a deal worth up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors.The agreement includes plans for preclinical research collaboration, options and licensing of T-cell engaging multispecific antibodies.AbCellera, which has a T-cell engager platform, will perform discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months.Jazz is granted an option in connection with each research program and, once it exercises its option, will have exclusive, global rights to develop and commercialize each program.AbCellera will receive $56 million in total upfront payments for the first two research programs, plus an additional $28 million due when the third program starts.If Jazz exercises its option for development, AbCellera will also be eligible to receive up to $792 million per program in option fees and development, regulatory and commercial","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","JAZZ":"爵士制药","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4121":"生命科学工具和服务","ABCL":"AbCellera Biologics","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4535":"淡马锡持仓","BK4532":"文艺复兴科技持仓","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Jazz Pharmaceuticals与AbCellera签署价值8.76亿美元的癌症治疗协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9,"JAZZ":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Jazz Pharmaceuticals and AbCellera agreed to a deal worth up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors. \n\n\n  The agreement includes plans for preclinical research collaboration, options and licensing of T-cell engaging multispecific antibodies. \n\n\n  AbCellera, which has a T-cell engager platform, will perform discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months. \n\n\n  Jazz is granted an option in connection with each research program and, once it exercises its option, will have exclusive, global rights to develop and commercialize each program. \n\n\n  AbCellera will receive $56 million in total upfront payments for the first two research programs, plus an additional $28 million due when the third program starts. \n\n\n  If Jazz exercises its option for development, AbCellera will also be eligible to receive up to $792 million per program in option fees and development, regulatory and commercial sales milestone payments. \n\n\n  AbCellera will also be eligible to receive tiered royalties on net sales ranging from the mid-single digits to the low double digits. \n\n\n  Jazz and AbCellera can also agree to start up to two additional programs. AbCellera can conduct certain activities for investigational new drug-enabling studies and can manufacture clinical supplies for any program under the collaboration. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 07:33 ET (11:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644743145","isCrawlerRequest":true}